TRVI Trevi Therapeutics
- 2.840
- -0.060-2.07%
- 2.840
- 0.0000.00%
Trevi Therapeutics News
Trevi Therapeutics Analyst Ratings
Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7
Buy Rating Affirmed for Trevi Therapeutics Amid Promising Clinical Advances and Solid Financial Position
Analysts Are Bullish on These Healthcare Stocks: MariMed (MRMD), Trevi Therapeutics (TRVI)
Trevi Therapeutics Analyst Ratings
Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Analysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Neurogene (NGNE)
Trevi Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)
Buy Rating for Trevi Therapeutics Anchored on Haduvio's Clinical Promise and Market Potential
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)
Trevi Therapeutics (TRVI) Receives a Buy From Stifel Nicolaus
Analysts' Top Healthcare Picks: Trevi Therapeutics (TRVI), Walgreens Boots Alliance (WBA)
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Ayr Wellness (OtherAYRWF) and Trevi Therapeutics (TRVI)
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Hookipa Pharma (HOOK) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Analysts Are Bullish on These Healthcare Stocks: Trevi Therapeutics (TRVI), Pliant Therapeutics (PLRX)
Analysts' Top Healthcare Picks: Trevi Therapeutics (TRVI), Prothena (PRTA)
Analysts Conflicted on These Healthcare Names: Curis (CRIS), Trevi Therapeutics (TRVI) and Prothena (PRTA)
Promising Future for Trevi Therapeutics: Buy Rating Justified by Robust Haduvio Data and Expected Developments
B.Riley Financial Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)
Analysis
Price Target
No Data
